Blog

Amyloidosis is a rare disease that occurs when abnormal proteins build up in tissues and organs throughout the body. This build-up can lead to a variety of health problems and…

We have already mentioned it several times: amyloidosis is a rare disease that is not well known to everyone, even to doctors. The fact that it is so little known…

The World Heart Federation (WHF) convened a special forum May 17-18, 2023 in Geneva, Switzerland, entitled “SHINING A LIGHT ON RARE CARDIOVASCULAR DISEASES” in advance of the 2023 World Heart…

Do you want to learn MORE about CLINICAL TRIAL? Over the past year Alnylam’s Patient Advocacy and Medical Writing teams have been collaborating to produce plain language summaries (PLS) of…

A look back at a most successful therapeutic trial for Amyloidosis !
We are pleased to report that the trial is very promising and paves the way for a new therapy.

Amyloidosis is a group of rare diseases characterised by the abnormal deposition of amyloid proteins (proteins that misfold or twist to form “amyloid fibrils”) in various organs and tissues of…

The 4th European ATTR amyloidosis meeting for patients and physicians will be held on 2 and 3 November. To register, go online to the official event website: www.attramyloidosis2023.com It will…

Amyloidosis is a recent disease, first described in 1838 by Rudolph Virchow, a German pathologist, who identified abnormal deposits in the tissue of deceased patients. Since then, much research has…

End-stage cardiac amyloidosis is an often-fatal disease that affects the ability of the heart to function properly. In recent years, heart transplantation has emerged as a viable option for patients…

HAC/TAC is proud to present the first-ever Canadian-specific ATTR Patient Summit
An event where we will be bringing together patients, families, physicians, healthcare professionals and industry in a weekend of knowledge exchange, shared experiences, and networking.
This ATTR Patient Summit will take place at the Hyatt Regency Hotel in downtown Toronto.